Use of antivenoms for the treatment of envenomation by Elapidae snakes in Guinea, Sub-Saharan Africa

Mamadou C Baldé, Jean-Philippe Chippaux, Mamadou Y Boiro, Roberto P Stock and Achille Massougbdji

Abstract

Background: In Guinea Elapids are responsible for 20% of envenomations. The associated case fatality rate (CFR) ranged 15-27%, irrespective of treatment.

Results: We studied 77 neurotoxic envenomations divided in 3 groups: a set of patients that received only traditional or symptomatic treatments, and two other groups that received either 2 or 4 initial vials of Antivipmyn® Africa renewed as necessary. CFR was 27.3%, 15.4% and 17.6%, respectively. Although antivenom treatment was likely to reduce CFR, it didn’t seem to have an obvious clinical benefit for the patients, suggesting a low treatment efficacy. Mean delay to treatment or clinical stages were not significantly different between the patients who recovered and the patients who died, or between groups. Interpretation of these results is complicated by the lack of systematic studies under comparable conditions. Of particular importance is the absence of assisted ventilation, available to patients in all the other clinical studies of neurotoxic envenomation.

Conclusion: The apparent lack of clinical benefit may have several causes. The hypothesis of a limited therapeutic window, i.e. an insufficient formation of antigen-antibody complexes once toxins are bound to their targets and/or distributed beyond the reach of antivenom, should be explored.

Keywords: Elapid, Neurotoxins, Treatment, Antivenom, Guinea, Africa

Background

The efficacy of immunotherapy and its role in the treatment of envenomation are well established and not in question, at least in Africa [1,2]. The limited availability of antivenoms has led several manufacturers from emergent countries to propose their services to alleviate this critical deficit [3-6]. Two clinical studies conducted in northern Cameroon in 1993 and 1996 established the safety of F(ab’)2-based antivenoms administered by perfusion or direct intravenous injection [7,8]. Between 2005 and 2006, a clinical study using Antivipmyn® Africa, with results judged to be very successful, was conducted in Benin [9]. However, these clinical studies were concerned essentially with envenomations caused by Viperidae, particularly *Echis ocellatus*, a species largely predominant in the savannas of West Africa. A clinical study in Guinea confirmed the apparent general efficacy and safety of Antivipmyn® Africa [10]. However, it revealed shortcomings regarding the treatment of envenomations by Elapidae.

We have reexamined the available records in Upper and Lower Guinea (Figure 1) to evaluate the efficacy and shortcomings of immunotherapy relative to the absence of specific treatment in patients with overt neurological symptoms due to envenomation by African Elapidae. Patients were divided into three groups according to treatment protocol.

Methods

An initial group of 33 patients was retrospectively composed after assemblage of clinical information from hospitalization registries of a health center in the region of Kankan (Upper Guinea). None of them had received antivenom as it was unavailable at that time. Two other groups were based on prospective clinical studies at the

© 2013 Baldé et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pasteur Institute of Guinea in Kindia (Lower Guinea) in order to ascertain the safety and efficacy of Antivipmyn® Africa under real field conditions, the results of which have been published elsewhere [10]. The second group included 26 patients who were treated during the years 2009 and 2010. Patients received an initial dose of 2 vials of antivenom renewed as a function of clinical evolution 3, 6, 12 and 24 hours after the first dose (low-dose group). Since the results appeared unsatisfactory, the design of the study was amended in 2011 to increase the dose of antivenom accordingly. The third group included 18 patients (but only 17 treated because one died on arrival before treatment). They received twice the initial dose (4 vials), renewed as a function of evolution 3, 6, 12 and 24 hours after the initial dose (high-dose group).

We included all bitten patients who had presented neurological disorders: local paresthesia, tremors and muscular contractions, palpebral ptosis, vision impairment, tinnitus, dysarthria, consciousness disorders, dyspnea, hypersecretion. The severity and surveillance

| Score | Symptoms |
|-------|----------|
| Grade 1 | Local paraesthesia (anesthesia, tingling, stinging) |
| Grade 2 | Hypersecretion (sweat, saliva) |
| Grade 3 | Impaired vision, hearing, speech, dysphagia |
| Grade 4 | Bilateral ptosis |
| Grade 5 | Severe dyspnea |
| Grade 6 | Severe consciousness disorders, motor and respiratory paralysis |

Figure 1 Location of survey sites in Guinea.

Figure 2 Flow chart of inclusion and outcome of patients from Upper and Lower Guinea.
### Table 2 Symptoms and time to death in patients of group 1

| N  | Time of the bite | Sex and age | Treatment                      | Symptoms at presentation                          | Time of the death | Time between bite and death |
|----|------------------|-------------|--------------------------------|---------------------------------------------------|------------------|----------------------------|
| 1  | 8:10 a.m.        | M – 15      | Traditional                    | Hypersalivation; blurred vision                   | 10:45 a.m.       | 2:35                       |
| 2  | 9:00 p.m.        | M – 43      | Symptomatic                    | Breathlessness                                    | 4:00 a.m.        | 7:00                       |
| 3  | 3:20 p.m.        | F – 56      | Traditional and symptomatic    | Weakness; sweat                                   | 11:10 p.m.       | 7:50                       |
| 4  | 11:00 a.m.       | M – 23      | Symptomatic                    | Posis                                            | 7:00 p.m.        | 8:00                       |
| 5  | 0:50 p.m.        | M – 17      | Traditional                    | Blurred vision                                    | 2:15 p.m.        | 1:25                       |
| 6  | 4:20 p.m.        | F – 32      | Traditional and symptomatic    | Consciousness disorders                           | 1:00 p.m.        | 20:40                      |
| 7  | 8:00 p.m.        | F – 8       | Symptomatic                    | Blurred vision and consciousness disorders        | 12:30 a.m.       | 16:30                      |
| 8  | 5:00 p.m.        | F – 36      | Traditional                    | Hypersalivation, consciousness disorders          | 4:10 a.m.        | 11:10                      |
| 9  | 2:30 p.m.        | M – 51      | Traditional and symptomatic    | Local bleeding; breathlessness                     | Day 2: 6:00 p.m. | 27:30                      |

### Table 3 Symptoms and time to death in patients of group 2 (low dose of antivenom)

| Patient | Time between bite and presentation | Clinical score on arrival | Snake species | Vials of antivenom | Associated symptoms                        | Outcome                   |
|---------|-----------------------------------|---------------------------|---------------|-------------------|--------------------------------------------|---------------------------|
| 8       | 3                                 | 4                         | D. viridis    | 2                 |                                            | Recovery H6               |
| 16      | 21                                | 5                         | D. viridis    | 4                 |                                            | Recovery H6               |
| 17      | 11                                | 3                         | D. viridis    | 1                 |                                            | Recovery H6               |
| 19      | 18                                | 6                         | D. polylepis  | 4                 | Edema                                     | Death H7                  |
| 20      | 48                                | 2                         | D. viridis    | 1                 |                                            | Recovery H3               |
| 26      | 5                                 | 5                         | D. viridis    | 4                 |                                            | Recovery H6               |
| 27      | 6                                 | 6                         | D. viridis    | 4                 | Local bleeding                            | Recovery H6               |
| 29      | 2                                 | 6                         | D. viridis    | 2                 | Local bleeding                            | Death H1                  |
| 33      | 47                                | 2                         | D. viridis    | 1                 |                                            | Recovery H3               |
| 37      | 2                                 | 1                         | D. viridis    | 2                 |                                            | Recovery H3               |
| 38      | 13                                | 3                         | D. viridis    | 1                 | Edema                                     | Recovery H3               |
| 53      | 15                                | 1                         | D. viridis    | 1                 | Local bleeding and edema                   | Recovery H3               |
| 59      | 4                                 | 4                         | D. viridis    | 2                 | Bleeding                                  | Recovery H3               |
| 71      | 10                                | 4                         | Edema         | 4                 |                                            | Recovery H6               |
| 77      | 20                                | 3                         | D. viridis    | 2                 | Edema                                     | Recovery H3               |
| 87      | 7                                 | 5                         | D. viridis    | 6                 |                                            | Recovery H6               |
| 88      | 4                                 | 5                         | D. viridis    | 4                 |                                            | Recovery H3               |
| 119     | 3                                 | 5                         | D. viridis    | 2                 |                                            | Recovery H3               |
| 123     | 3                                 | 4                         | D. viridis    | 1                 |                                            | Recovery H3               |
| 124     | 10                                | 5                         | D. viridis    | 2                 |                                            | Recovery H3               |
| 130     | 3                                 | 1                         | D. polylepis  | 2                 | Local bleeding                            | Recovery H6               |
| 134     | 14                                | 3                         | Naja sp.      | 4                 | Edema                                     | Death H4                  |
| 138     | 4                                 | 2                         | D. polylepis  | 3                 |                                            | Recovery H6               |
| 141     | 2                                 | 2                         | D. polylepis  | 6                 |                                            | Death H7                  |
| 148     | 6                                 | 4                         | Naja sp.      | 2                 | Edema                                     | Recovery H3               |
| 149     | 1                                 | 2                         | N. melanoleuca| 1                 | Local bleeding                            | Recovery H6               |

H: hour after initial antivenom dose.
of envenomation were evaluated by means of scores (Table 1) [10].

Antivipmyn® Africa, manufactured by Biodon Institute (Mexico), is composed of highly purified lyophilized F(ab')2 immunoglobulin fragments [11]. It is produced by immunization of horses with the venoms of *Bitis gabonica*, *B. arietans*, *Echis ocellatus*, *E. leucogaster*, *E. pyramidum*, *Naja haje*, *N. melanoleuca*, *N. nigricollis*, *N. pallida*, *Dendroaspis viridis* and *D. polylepis*. Preclinical testing indicated a specific neutralizing potency of more than 250 LD50 per vial against all relevant species [11]. Administration of the antivenom was always by direct intravenous push as detailed elsewhere and modified as indicated in the Results section [9].

Statistical analysis used Wilcoxon rank sum test for time to presentation, score and time to death, and Student's t test for treatment doses, with p = 0.05.

**Results and discussion**

In the region of Upper Guinea, we analyzed 226 records of patients bitten between 2005 and 2006. At the Pasteur Institute of Guinea, in Lower Guinea, 521 patients were treated from 2009 to 2011.

### Table 4 Symptoms and time to death in patients of group 3 (high dose of antivenom); one death (#11) was not recorded because the patient died before treatment, less than three hours after the bite

| Patient | Time between bite and presentation | Clinical score on arrival | Snake species | Vials of antivenom | Associated symptoms | Evolution |
|---------|-----------------------------------|---------------------------|---------------|-------------------|---------------------|-----------|
| 2       | 7                                 | 4                         | *D. viridis*  | 4                 | Edema               | Recovery H31 |
| 3       | 7                                 | 4                         | *Naja sp.*    | 4                 | Edema               | Recovery H39 |
| 4       | 2                                 | 1                         | *Naja sp.*    | 4                 |                     | Recovery H50 |
| 5       | 3                                 | 2                         | *Naja sp.*    | 4                 |                     | Recovery H51 |
| 6       | 3                                 | 5                         | *D. polylepis*| 4                 | Local bleeding      | Death H1   |
| 7       | 1                                 | 1                         | *N. nigricollis*| 4               | Edema               | Recovery H40 |
| 8       | 2                                 | 4                         | *Naja sp.*    | 4                 | Local bleeding      | Death H2   |
| 9       | 4                                 | 1                         | *Naja sp.*    | 4                 | Local bleeding      | Recovery H38 |
| 10      | 1                                 | 2                         | *Naja sp.*    | 4                 |                     | Recovery H40 |
| 12      | 4                                 | 4                         | *Naja sp.*    | 4                 | Edema               | Recovery H52 |
| 13      | 4                                 | 1                         | *Naja sp.*    | 4                 |                     | Recovery H38 |
| 14      | 5                                 | 6                         | *Naja sp.*    | 4                 | Edema               | Recovery H50 |
| 15      | 6                                 | 4                         | *D. viridis*  | 4                 |                     | Recovery H10 |
| 16      | 5                                 | 3                         | *Naja sp.*    | 4                 |                     | Recovery H3 |
| 17      | 10                                | 6                         | *Naja sp.*    | 4                 |                     | Recovery H34 |
| 18      | 18                                | 2                         | *Naja sp.*    | 4                 |                     | Recovery H66 |

H: hour after initial antivenom dose.

### Table 5 Comparison of score and time to death in the 3 groups

|                  | Group 1 (no antivenom) | Group 2 (low dose) | Group 3 (high dose) |
|------------------|------------------------|--------------------|---------------------|
| Number of cases  | 33                     | 26                 | 17                  |
| Score at presentation | Cured patients = ?     | Cured patients = 4 [2–5] | Cured patients = 2.5 [1.3–4] |
| Median [Q:0.25-0.75] | Fatalities = 5 [3-6]* | Fatalities = 4.5 [2.8-6] | Fatalities = 4 [3-4.5] |
| Mean of antivenom ± SD [95%CI] | 0                      | 26.2 ± 5.9 mL | 41.2 ± 2.3 mL |
| Number of fatalities | 9 (27.3%)              | 15.4%             | 3 (17.6%)          |
| Time to presentation | –                     | Cured patients = 5 [3.3-9.3] | Cured patients = 3 [3.3-10] |
| Median [Q: 0.25-0.75] | Fatalities = 2.5 [2-6.8] |                       | Fatalities = 2 [2-8] |
| Time to death    | 8 [7–13.5]             | 5.5 [3.3-7]       | 4 [4–4]            |

*Score established retrospectively from recorded clinical symptoms.
The data collected as well as the outcomes are summarized in Figure 2 and Tables 2, 3, 4, 5. There were no significant differences either in the neurological scores on arrival or in the delay of treatment between the three groups. Administration of antivenom, independently of dose, did not significantly reduce CFR between the untreated group from Upper Guinea and either group treated in Lower Guinea.

Data collection varied among the three groups due to the conditions of the surveys and the treatment protocols. The study in Upper Guinea was retrospective, a fact that restricted the available information. In the two groups from Lower Guinea, the treatment protocol changed due to the apparently low efficacy of the Antivipmyn® Africa antivenom, as well as the modalities of patient surveillance and the recovery criteria, which introduced some intergroup heterogeneity. Some comparisons could not be made among all groups, such as the delay in receiving a consultation (this variable was not available for the untreated group) or the time between bite and recovery in surviving patients (since none of the groups followed the same recovery criteria). As a consequence, comparability between groups, as well as patient series described in the literature, is limited. It appears, however, that treatment failures are common even when employing high doses of antivenom associated with intensive symptomatic treatment (mechanical ventilation, prostigmine etc.).

Our analysis of the records from the two health centers allowed us to identify 77 patients who, on arrival, presented neurological troubles strongly suggestive of envenomation by Elapidae. In some cases species could be identified either by examination of the specimen or by a description. Furthermore, the observed symptoms permitted, with a little experience, educated guesses of the species or at least genera responsible for the envenomation (Table 6). Some species of Naja are responsible for an isolated neurological syndrome (syndrome cobraïque) (Figure 3), or associated with local necrosis in the case of envenomations by Naja nigricollis and N. katiensis (both spitting cobras). Dendroaspis (in Guinea, D. viridis and D. polylepis) envenomation is also associated with the syndrome, a muscarinic symptomatology manifested by abundant sweat, sialorrhea, vomit, diarrhea and mydriasis [12] (Figure 4). We do not have information on envenomations by Pseudohaje nigra.

A delay until consultation, which is detailed only for patients in groups 2 and 3, appears to be a decisive factor insofar as it delays treatment, which is more effective the earlier it is administered [13-15]. The lack of significance between the groups could result from the small number of patients. Paradoxically, the delay in consultation is longer (although not significantly) in patients who recovered in comparison to those who died (Table 5). However, some severely envenomed patient could have died before reaching the health center. But there is no evidence to support this hypothesis. In addition, the time between bite and fatality in group 3 is remarkably shorter and significantly different from that of the other two groups. The duration of hospitalization is also much shorter, which suggests either that envenomations were more severe (even if scores on arrival were similar) or that shorter delays were declared.

The efficacy of Antivipmyn® Africa in these cases is therefore directly questioned. There is no reason to doubt its experimental neutralization capacity, but these results do not seem to be transposed to the clinical situation [11]. Dosage does not seem to be the issue, as the same results are apparent at lower and higher doses. In our study, doubling the initial dose did not lead to a difference in the maximal dose administered permitted, with a little experience, educated guesses of the species or at least genera responsible for the envenomation (Table 6). Some species of Naja are responsible for an isolated neurological syndrome (syndrome cobraïque) (Figure 3), or associated with local necrosis in the case of envenomations by Naja nigricollis and N. katiensis (both spitting cobras). Dendroaspis (in Guinea, D. viridis and D. polylepis) envenomation is also associated with the syndrome, a muscarinic symptomatology manifested by abundant sweat, sialorrhea, vomit, diarrhea and mydriasis [12] (Figure 4). We do not have information on envenomations by Pseudohaje nigra.

A delay until consultation, which is detailed only for patients in groups 2 and 3, appears to be a decisive factor insofar as it delays treatment, which is more effective the earlier it is administered [13-15]. The lack of significance between the groups could result from the small number of patients. Paradoxically, the delay in consultation is longer (although not significantly) in patients who recovered in comparison to those who died (Table 5). However, some severely envenomed patient could have died before reaching the health center. But there is no evidence to support this hypothesis. In addition, the time between bite and fatality in group 3 is remarkably shorter and significantly different from that of the other two groups. The duration of hospitalization is also much shorter, which suggests either that envenomations were more severe (even if scores on arrival were similar) or that shorter delays were declared.

The efficacy of Antivipmyn® Africa in these cases is therefore directly questioned. There is no reason to doubt its experimental neutralization capacity, but these results do not seem to be transposed to the clinical situation [11]. Dosage does not seem to be the issue, as the same results are apparent at lower and higher doses. In our study, doubling the initial dose did not lead to a difference in the maximal dose administered

Table 6 Elapid species and distribution in Upper and Lower Guinea

| Species            | Upper Guinea | Lower Guinea | Symptoms                                      |
|--------------------|--------------|--------------|-----------------------------------------------|
| Naja nigricollis   | Common       | Common       | Local necrosis, neurotoxic signs               |
| Naja katiensis     | Common       | Absent       | Neurotoxic signs, local necrosis              |
| Naja melanoleuca   | Common       | Common       | Neurotoxic signs                              |
| Dendroaspis viridis| Present      | Common       | Neurotoxic signs, muscarinic syndrome          |
| Dendroaspis polylepis| Present     | Present      | Neurotoxic signs, muscarinic syndrome          |
| Pseudohaje nigra   | Absent       | Rare         | No envenomation recorded                      |

Figure 3 Neurotoxic syndrome due to Naja melanoleuca bite (note pathognomonic ptosis) Photo by E. Stahel.
to the patients (60 mL), a fact that suggests that the criteria for re-administration of antivenom were not apparent during the monitoring of the patients. But despite demonstrable neutralization in the animal model, it is possible that the venom of a particular species (of a total of four possible ones in Lower Guinea) is poorly neutralized by the antivenom in humans; given the small sample of patients and the lack of unambiguous snake identification in most of them, this could skew the overall results and mask some measure of overall efficacy. It is also possible that the therapeutic window is simply very narrow for some or all venoms.

More generally in Elapid envenomations, such low apparent clinical efficacy has also been observed by numerous authors who have obtained similar results, even at much higher doses (Table 7). Furthermore, in all other studies, antivenom use was associated with mechanical ventilation on demand, as well as other symptomatic treatments such as cholinesterase inhibitors. These were not available for patients in the present study. Although the species, and therefore the toxicity and mode of action of their venoms, are different, and the antivenoms – whose neutralizing capacities are also variable – are not the same, it is important to note that the treatment of Elapid envenomations is less effective than treatment of those inflicted by Viperidae. In fact, the doses reported by numerous authors (surpassing occasionally even a hundred vials, a tendency which confirms a low level of efficacy) seem unreasonable, with regard to both the quantity of heterologous protein administered and the cost of treatment, already prohibitive for extremely poor patients even at much lower doses.

In hemorrhagic envenomations in the West African savanna, a rapid arrest of hemorrhage and coagulopathy was apparent after antivenom administration, requiring no additional care to remove most patients from immediate danger of life-threatening hemorrhage [7-9]. The lack of therapeutic response in neurotoxic envenomations, however, suggests that antivenom alone may not suffice to ensure a sufficiently rapid recovery to prevent respiratory failure and death. Under the extremely precarious conditions of this study, potential benefits of antivenom administration, such as a speedier recovery from respiratory paralysis, would be masked by the unavailability of assisted ventilation.

One possibility is that the antivenom has a low efficacy after neurotoxins are fixed on the neuromuscular receptors, which usually happens in the first few hours after the bite [26]. In this view, the problem is immunoochemical: those epitopes recognized by the antibodies would be masked on receptor-bound toxins and this would in turn

---

**Table 7 Antivenom doses and mortality observed in the literature**

| Countries       | Patients (n) | Mean doses (mL [range]) | # deaths (CFR) | Supportive measures* | Reference |
|-----------------|--------------|-------------------------|----------------|----------------------|-----------|
| Guinea          | 26           | 25 mL [10–60]           | 4 (15%)        | No                   | Group 2 this study |
| Guinea          | 17           | 40 mL [40–60]           | 3 (18%)        | No                   | Group 3 this study |
| India           | 28           | 150 mL [300–1,600]      | 0              | VS                   | [16]      |
| India           | 27           | 600 mL [300–1,600]      | 3 (11%)        | VS                   | [16]      |
| Sri Lanka       | 87           | > 100 mL [100–200]      | 5 (6%)         | VS                   | [17]      |
| Sri Lanka       | 25           | 100 mL [80–200]         | 2 (8%)         | VS                   | [18]      |
| India           | 37           | 150 mL [10–100]         | 11 (22%)       | VS, AC               | [19]      |
| Taiwan          | 22           | 30 mL [10–100]          | 0              | VS                   | [20]      |
| Papua New Guinea| 139          | 50 mL [50–1900]         | 6 (4.3%)       | VS                   | [13]      |
| Papua New Guinea| 31           | 25 mL [50–100]          | 0              | VS, AC               | [13]      |
| India           | 14           | 60 mL [50–100]          | 1 (7%)         | VS                   | [21]      |
| India           | 12           | 120 mL [50–100]         | 0              | VS                   | [21]      |
| Thailand        | 68           | 100 mL [50–100]         | 0              | VS                   | [22]      |
| India           | 86           | 510 mL [50–1900]        | 3 (3.9%)       | VS                   | [23]      |
| Papua New Guinea| 156          | 50 mL [50–1900]         | 3 (1.9%)       | VS                   | [14]      |
| Vietnam         | 42           | 50 mL [50–100]          | 0              | VS                   | [24]      |
| Thailand        | 85           | 40 mL [10–200]          | 1 (1%)         | VS                   | [25]      |

VS: ventilatory support; AC: anticholinesterase; §the patients died from extensive necrosis; *three patients died before treatment.
prevent toxin-antibody complex formation, neutralization and elimination.

A second hypothesis that merits attention is pharmacokinetic: the toxin-antibody encounter does not occur because the antigen and the antibody are not found in the same biological compartment. The antivenom is largely present in the vascular compartment [27]. It is in this compartment that antigen-antibody complex formation occurs, provided that the relevant venom components are there as well. It has been clearly shown that Viperidae venoms are found in the blood, where they are bound by antivenom [28]. To the best of our knowledge, it has never been shown that neurotoxins from Elapidae venoms were present in high proportion in the vascular compartment, nor that neurotoxins are bound by F(ab’)2 after intravenous administration.

Conclusion
During a clinical study in Guinea under true field conditions, the administration of purified immunoglobin fragments to treat neurotoxic envenomation due to Elapidae has proven a disappointment, in agreement with the results of numerous other clinical studies.

The hypothesis of insufficient venom neutralization is difficult to maintain because, on one hand, the experimental neutralization of venoms is generally acceptable and, on the other hand, this divergence has been noted for many elapid venoms and antivenoms throughout the world. Alternatively, a hypothesis of an absence of toxin-antibody complex formation merits consideration; it could come about by epitope masking on receptor-bound toxins and/or by a failure of the antibodies to encounter the relevant toxins due to pharmacokinetic constraints. In the first case, the only recourse would be very early administration of antivenom or the development of neutralizing antibodies against epitopes not masked on receptor-bound toxins. In the second case, another route of antivenom administration should be considered.

In the meantime, it is advisable to administer antivenom as early as possible after the bite to attempt to eliminate available venom antigens and to secure assisted ventilation in case the patient presents the onset of respiratory distress.

Consent
Written informed consent was obtained from the patients for publication of this study and any accompanying images.

Competing interests
The authors declare that there are no conflicts of interest.

Authors’ contributions
JPC, RPS and AM designed the study. MCB, JPC and AM wrote the protocol. MCB and MYB performed the field study. MCB, JPC analysed the results. JPC wrote the draft. All authors corrected and validated the paper. MCB and JPC are guarantors of the paper.

Author details
1Institut Pasteur de Guinée, Kindia, Guinée. 2Institut de Recherche pour le Développement, Cotonou, Bénin. “Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Cotonou, Bénin. 3Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, México.

Received: 1 October 2012 Accepted: 30 November 2012
Published: 28 March 2013

References
1. Chippaux JP: The development and use of immunotherapy in Africa. Toxicon 1998, 36(1):1503–1506.
2. Chippaux JP: Snakebite in Africa: current situation and urgent needs. In Reptile venoms and toxins. Edited by Mackessy SP, Boca Raton: Taylor, Francis/CRC, Press; 2000:445–465.
3. Chippaux JP: The treatment of snake bites: analysis of requirements and assessment of therapeutic efficacy in tropical Africa. In Perspectives in molecular toxicology. Edited by Ménez A. Chichester: John Wiley & Sons, Ltd; 2002:457–472.
4. Chippaux JP: Estimate of the burden of snakebites in sub-Saharan Africa: a meta-analytic approach. Toxicon 2011, 57(4):586–599.
5. Stock RP, Massougbo TJ, Alagón A, Chippaux JP: Bringing antivenom to Sub-Saharan Africa. Nat Biotechnol 2007, 25(2):173–177.
6. Theakston RD, Warrell DA, Griffiths E: Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003, 41(5):541–557.
7. Chippaux JP, Lang J, Eddine SA, Fagot P, Rage V, Peyriexuc JC, et al: Clinical safety of a polyvalent F(ab’)2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans R Soc Trop Med Hyg 1998, 92(6):657–662.
8. Chippaux JP, Lang J, Amadi-Eddine S, Fagot P, Le Mener V: Treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab’)2: results of a field trial in northern Cameroon. Am J Trop Med Hyg 1999, 61(6):1017–1018.
9. Chippaux JP, Massougbo TJ, Stock RP, Alagón A: Clinical trial of an F(ab’)2 polyvalent equine antivenom for African snakebites in Benin. Am J Trop Med Hyg 2007, 77(3):538–546.
10. Baldé MC, Chippaux JP, Bairo MY, Stock R, Massougbo TJ: Etude clinique de la tolérance et de l’efficacité d’un sérum anti-ophidien polyvalent F(ab’)2 pour l’Afrique à Kindia, Guinée. Bull Soc Pathol Exot 2012, 105(3):157–161.
11. Farnos-Cerrillo B, de Roodt AR, Chippaux JP, Olgué L, Casacada A, Guzmán G, et al: Characterization of a new polyvalent antivenom (Antivipmyn Africa®) against African vipers and elapids. Toxicon 2008, 52(8):881–888.
12. Chippaux JP, Courtois B, Roumet D, Eyibiyi R: Envenoming par morsure de Mamba (Dendroaspis viridis): à propos d’une observation à évolution favorable. Med Trop 1977, 37(5):545–549.
13. Lalilo DG, Trevett AJ, Korinthona A, Nwokolo N, Laurendon IF, Paul M, et al: Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenin. Am J Trop Med Hyg 1995, 52(6):525–531.
14. Trevett AJ, Lalilo DG, Nwokolo NC, Narasi S, Kevau IH, Theakston RD, et al: The efficacy of antivenin in the treatment of bites by the Papuan taipan (Oxyuranus scutellatus canni), Trans R Soc Trop Med Hyg 1995, 89(3):322–325.
15. Trevett AJ, Lalilo DG, Nwokolo NC, Narasi S, Kevau IH, Theakston RD, et al: Failure of 3,4-diaminopyridine and edrophonium to produce significant clinical benefit in neurotoxicity following the bite of Papuan taipan (Oxyuranus scutellatus canni), Trans R Soc Trop Med Hyg 1995, 89(4):444–446.
16. Agarwal R, Agarwal AN, Gupta D, Behera D, Jindal SK: Low dose of snake antivenin is as effective as high dose in patients with severe neurotoxic snake envenoming. Emerg Med J 2005, 22(6):397–399.
17. Ariaratnam CA, Sheriff MH, Theakston RD, Warrell DA: Distinctive epidemiologic and clinical features of common krait (Bungarus caeruleus) bites in Sri Lanka. Am J Trop Med Hyg 2008, 79(3):458–462.
18. Kularatne SA, Budagoda BD, Gawaramanna IB, Kularatne WK: Epidemiologic, clinical profile and management issues of cobra (Naja naja) bites in Sri Lanka: first authenticated case series. Trans R Soc Trop Med Hyg 2009, 103(9):924–930.
19. Bavaskar HS, Bavaskar PH: Envenoming by the common krait (Bungarus caeruleus) and Asian cobra (Naja naja): clinical manifestations and their management in a rural setting. Wilderness Environ Med 2004, 15(4):257–266.
20. Chieh-Fan C, Tzeng-Jih L, Wen-Chi H, Hua-Wei Y: Appropriate antivenom doses for six types of envenomations caused by snakes in Taiwan. J Venom Anim Toxins incl Trop Dis 2009, 15(3):479–490.

21. Paul V, Pratibha S, Prahald RA, Earall J, Francis S, Lewis F: High-dose anti-snake venom versus low-dose anti-snake venom in the treatment of poisonous snake bites – a critical study. J Assoc Physicians India 2004, 52:14–17.

22. Pochanugool C, Limthongkul S, Wilde H: Management of thai cobra bites with a single bolus of antivenin. Wilderness Environ Med 1997, 8(1):20–23.

23. Sharma N, Chauhan S, Faruqi S, Bhat P, Varma S: Snake envenomation in a north Indian hospital. Emerg Med J 2005, 22(2):118–120.

24. Trinh KX, Khac QL, Trinh LX, Wanell DA: Hyponatremia, rhabdomyolysis, alterations in blood pressure and persistent mydriasis in patients envenomed by Malayan kraits (Bungarus candidus) in southern Viet Nam. Toxicon 2010, 56(6):1070–1075.

25. Wongtongkam N, Wilde H, Sithi-Amorn C, Ratanabanangkoon K: A study of Thai cobra (Naja kaouthia) bites in Thailand. Mil Med 2005, 170(4):336–341.

26. Boulain JC, Ménez A: Neurotoxin-specific immunoglobulins accelerate dissociation of the neurotoxin-acetylcholine receptor complex. Science 1982, 217(4561):732–733.

27. Sevcik C, Salazar V, Díaz P, D’Suze G: Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of Fab’2 antivenoms and other drugs. Toxicon 2007, 50(5):653–665.

28. Rivière G, Choumet V, Salou B, Debray M, Bon C: Absorption and elimination of viper venom after antivenom administration. J Pharmacol Exp Ther 1998, 285(2):490–495.

doi:10.1186/1678-9199-19-6

Cite this article as: Baldé et al.: Use of antivenoms for the treatment of envenomation by Elapidae snakes in Guinea, Sub-Saharan Africa. Journal of Venomous Animals and Toxins including Tropical Diseases 2013 19:6.